EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of neoadjuvant paclitaxel in breast angiosarcoma—Impact on surgical resection and response rates

Luke V Selby, Emma Clark, James L Chen, Gabriel Tinoco, Joal D Beane, Raphael E Pollock, David Liebner, Valerie P Grignol

Journal of Surgical Oncology · 2024-09 · 130 (3) · 579-585

DOI: 10.1002/jso.27772 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 17.07.2024. Verfasst von Luke V Selby und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Hemangiosarcoma, Breast Neoplasms, Paclitaxel, Neoadjuvant Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Breast angiosarcoma is a tumor that can arise as a primary breast tumor or in association with prior radiation therapy. Angiosarcomas are uniquely sensitive to paclitaxel. This study evaluated the impact neoadjuvant paclitaxel (NAC) therapy has on surgical outcomes, tumor recurrence, and survival in breast angiosarcomas.

Methods

Patients with angiosarcoma of the breast, either primary or radiation‐associated, were identified from a prospective institutional database. Patients receiving NAC were compared to those treated with upfront surgery. Clinical and pathological variables were compared using Student's t ‐test or Fisher's exact test, differences in survival were calculated using Kaplan–Meier methods.

Results

Twenty‐four patients with angiosarcoma of the breast were identified, 10 with primary angiosarcoma and 14 with radiation‐associated angiosarcoma. Twelve patients received NAC, 6 of each with primary angiosarcoma or radiation‐associated angiosarcoma. Of these 12 patients, 11 had a margin negative resection (91%) of which, nine had a complete pathological response on surgical pathology. Of the 12 surgery‐first patients, four ( n = 4/12, 33%) had positive surgical margins, two of the four underwent reoperation. With a median follow‐up of 16 months, four NAC patients had recurrence (33%) compared to six patients in the surgery‐first group (58%) ( p = 0.41). While not statistically significant, NAC patients had a 33% less risk of recurring compared to surgery‐first patients ([hazard ratio =0.67 (95% confidence interval 0.16–2.72; p = 0.6]).

Conclusion

NAC for breast angiosarcoma may be associated with high rates of complete pathological response and margin‐negative resection. However, this did not impact overall survival. Future prospective control studies and longer follow‐up periods are warranted to understand the impact on recurrence and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemangiosarcomaBreast NeoplasmsPaclitaxelNeoadjuvant TherapyAntineoplastic Agents, PhytogenicHumansFemaleMiddle AgedAgedAdultNeoplasm Recurrence, LocalProspective StudiesFollow-Up StudiesAged, 80 and overMastectomyRetrospective StudiesSurvival Rate

Stichwörter der Autor:innen

breast angiosarcomabreast cancerneoadjuvant systemic therapyradiation associated sarcoma

Substanzen

PaclitaxelAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.
  • Department of Surgery, Division of Colorectal and Oncologic Surgery, University of Kansas School of Medicine, Kansas City, Kansas, USA.
  • The Ohio State University School of Medicine, Ohio State University, Columbus, Ohio, USA.
  • Department of Surgery, Wright State University, Dayton, Ohio, USA.
  • Department of Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Zitieren

APA

Selby, L. V., Clark, E., Chen, J. L., Tinoco, G., Beane, J. D., Pollock, R. E., Liebner, D., & Grignol, V. P. (2024). Use of neoadjuvant paclitaxel in breast angiosarcoma—Impact on surgical resection and response rates. Journal of Surgical Oncology, 130(3), 579-585. https://doi.org/10.1002/jso.27772

Vancouver

Selby LV, Clark E, Chen JL, Tinoco G, Beane JD, Pollock RE, et al. Use of neoadjuvant paclitaxel in breast angiosarcoma—Impact on surgical resection and response rates. Journal of Surgical Oncology. 2024;130(3):579-585. doi:10.1002/jso.27772

BibTeX
@article{Selby2024,
  author = {Selby, Luke V and Clark, Emma and Chen, James L and Tinoco, Gabriel and Beane, Joal D and Pollock, Raphael E and Liebner, David and Grignol, Valerie P},
  title = {Use of neoadjuvant paclitaxel in breast angiosarcoma—Impact on surgical resection and response rates},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  volume = {130},
  number = {3},
  pages = {579--585},
  doi = {10.1002/jso.27772}
}
Kostenlos starten →